InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-16.5%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Hall Brett Matthew, Directeur Scientifique. Officer active across 1 company, notably Immuneering Corp. Cumulatively, 7 filings have been recorded. Split: 2 buys · 0 sell. Total volume traded: €17k. Activity tracked since 23 March 2022. The latest transaction was disclosed on 15 March 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations7 total
6,211 shares@ US$1.6235.4% of flowClass A Common StockSEC:0001790340-24-000034:0
2,551 shares@ US$3.920.0028% mcap55.4% of flowClass A Common StockSEC:0001415889-22-005796:0
Ideal exit: 19 Feb 2023 (T+270)
1,050 shares@ US$7.910.0023% mcap44.6% of flowClass A Common StockSEC:0001415889-22-003305:0
Ideal exit: 18 Dec 2022 (T+270)
322,691 sharesClass A Common StockSEC:0001415889-21-006188
322,691 sharesClass A Common StockSEC:0001415889-21-006188:0
5,040 sharesClass A Common StockSEC:0001104659-21-099733
5,040 sharesClass A Common StockSEC:0001104659-21-099733:0
7 of 7 declarations
About Hall Brett Matthew
Brett Matthew Hall is the Chief Scientific Officer at Immuneering Corp. In this role, he is responsible for leading scientific research and product development. Hall plays a key role in innovation and advancing the company's therapeutic solutions. His scientific expertise is essential for supporting Immuneering's mission to provide advanced treatments.
